for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CASI Pharmaceuticals Inc

CASI.OQ

Latest Trade

1.60USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.32

 - 

3.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.60
Open
--
Volume
--
3M AVG Volume
43.36
Today's High
--
Today's Low
--
52 Week High
3.90
52 Week Low
1.32
Shares Out (MIL)
139.80
Market Cap (MIL)
220.88
Forward P/E
-5.30
Dividend (Yield %)
--

Next Event

Q2 2021 CASI Pharmaceuticals Inc Earnings Release

Latest Developments

More

CASI Pharmaceuticals Announces Q1 Revenue Of $5.7 Mln

Casi Pharmaceuticals Announces Pricing Of $32.5 Mln Public Offering Of Common Stock

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Industry

Biotechnology & Drugs

Contact Info

9620 Medical Center Dr Ste 300

ROCKVILLE, MD

20850-3396

United States

+1.240.8642600

http://www.casipharmaceuticals.com/

Executive Leadership

Wei-Wu He

Chairman of the Board, Chief Executive Officer

Wei Zhang

President, President of CASI China

Alexander A. Zukiwski

Chief Medical Officer

James Z. Huang

Independent Director

Franklin C. Salisbury

Independent Director

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.320

2019

-0.470

2020

-0.440

2021(E)

-0.298
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.64
Price To Book (MRQ)
2.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.99
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-56.64
Return on Equity (TTM)
-42.78

Latest News

Latest News

BRIEF-Casi Pharmaceuticals Unit Entered Into Loan Agreement With Juventas Cell Therapy Ltd

* CASI PHARMACEUTICALS - ON JUNE 8, UNIT ENTERED INTO LOAN AGREEMENT WITH JUVENTAS CELL THERAPY LTD

BRIEF-CASI Pharma Submits Application To Conduct Study For Antibody Program

* CASI PHARMACEUTICALS ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION (IND) TO CONDUCT PHASE 1 STUDY FOR ANTI-38 MONOCLONAL ANTIBODY PROGRAM

BRIEF-Casi Pharmaceuticals Reports First Quarter 2020 Financial Results

* CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Casi Pharmaceuticals Announces Full Year 2019 Financial Results

* CASI PHARMACEUTICALS ANNOUNCES FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Casi Pharmaceuticals Says CFO George Chi's Employment Will Cease Effective February 21

* CASI PHARMACEUTICALS - CO'S CFO GEORGE CHI'S EMPLOYMENT WILL CEASE EFFECTIVE FEBRUARY 21, 2020 Source: (https://bit.ly/2P9o9o4) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up